78 related articles for article (PubMed ID: 9329561)
1. Cobas Core CA 19-9 II EIA: new CA 19-9 enzyme immunoassay with high correlation to radioimmunoassays.
Birk B; Henne V; Hipp B; Meyer A
Anticancer Res; 1997; 17(4B):2911-4. PubMed ID: 9329561
[TBL] [Abstract][Full Text] [Related]
2. Development of a new automated enzyme immunoassay for the determination of neuron-specific enolase.
Sterk M; Oenings A; Eymann E; Roos W
Anticancer Res; 1999; 19(4A):2759-62. PubMed ID: 10470236
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of COBAS CORE anti-HIV-1/HIV-2 EIA DAGS for the detection of antibodies to HIV by COBAS CORE].
Kodama T; Nada T; Yamamoto H; Morishita Y; Iinuma Y; Ichiyama S
Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 1999; 10(1):43-50. PubMed ID: 10415449
[TBL] [Abstract][Full Text] [Related]
4. [CA 19-9 enzyme immunoassay].
Ota H; Odani H; Watanabe H; Satomura Y; Takemori Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
Gan No Rinsho; 1986 Aug; 32(9):993-7. PubMed ID: 3528560
[TBL] [Abstract][Full Text] [Related]
5. Selective detection of autoimmune antibodies to single- and double-stranded DNA by enzyme immunoassay.
Makowski GS; Ramsby ML
Ann Clin Lab Sci; 2003; 33(2):142-8. PubMed ID: 12817617
[TBL] [Abstract][Full Text] [Related]
6. [A basic and clinical study of CA 19-9-MP-Mitsui kit for determination of CA 19-9].
Ishii M; Iida M; Seino Y
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2779-86. PubMed ID: 7993114
[TBL] [Abstract][Full Text] [Related]
7. Performance of a conventional enzyme immunoassay for hepatitis C virus core antigen in the early phases of hepatitis C infection.
Aoyagi K; Iida K; Ohue C; Matsunaga Y; Tanaka E; Kiyosawa K; Yagi S
Clin Lab; 2001; 47(3-4):119-27. PubMed ID: 11294574
[TBL] [Abstract][Full Text] [Related]
8. Automated Cobas Core PSA assays: sensitive, precise, and specific measurement of PSA-total and PSA-total/PSA-free ratio.
Groche D; Trebo R; Peters I; Pfleiderer P
Anticancer Res; 1999; 19(4A):2767-70. PubMed ID: 10470238
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.
Ronsin C; Pillet A; Bali C; Denoyel GA
J Clin Microbiol; 2006 Apr; 44(4):1390-9. PubMed ID: 16597867
[TBL] [Abstract][Full Text] [Related]
10. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system.
Hochberger S; Althof D; Gallegos de Schrott R; Nachbaur N; Röck H; Leying H
J Clin Virol; 2006 Apr; 35(4):373-80. PubMed ID: 16461000
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the Cobas Amplicor HIV-1 Monitor Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples.
Berger A; Scherzed L; Stürmer M; Preiser W; Doerr HW; Rabenau HF
J Clin Virol; 2005 May; 33(1):43-51. PubMed ID: 15797364
[TBL] [Abstract][Full Text] [Related]
12. EIA versus RIA in detecting carcinoembryonic antigen level of patients with metastatic colorectal cancer.
Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2004; 51(55):136-41. PubMed ID: 15011849
[TBL] [Abstract][Full Text] [Related]
13. Technical performance of the Elecsys CA 72-4 test--development and field study.
Filella X; Friese S; Roth HJ; Nussbaum S; Wehnl B
Anticancer Res; 2000; 20(6D):5229-32. PubMed ID: 11326700
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the new Cobas Core IgE Total EIA in comparison to three commercial IgE immunoassays.
de Weck AL; Schluchter M; Girardin P
J Investig Allergol Clin Immunol; 1994; 4(1):5-11. PubMed ID: 8081542
[TBL] [Abstract][Full Text] [Related]
15. Beta-2-microglobulin--a rapid and automated determination for a broad range of clinical applications.
Henne V; Frei P; Bürgisser P
Anticancer Res; 1997; 17(4B):2915-8. PubMed ID: 9329562
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the test methods (KRYPTOR, ES 600 and CIS-RIA) for CEA, CA 15-3 and CA 125 follow-up and ONCOCHECK-quality control.
Bauer T; Charl S; Sturm G
Anticancer Res; 2000; 20(6D):5245-7. PubMed ID: 11326703
[TBL] [Abstract][Full Text] [Related]
17. Multicenter evaluation of the Elecsys CA 125 II assay.
Hubl W; Chan DW; Van Ingen HE; Miyachi H; Molina R; Filella X; Pitzel L; Ruibal A; Rymer JC; Bagnard G; Domke I
Anticancer Res; 1999; 19(4A):2727-33. PubMed ID: 10470230
[TBL] [Abstract][Full Text] [Related]
18. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
19. Clinical performance of the new rRoche COBAS TaqMan HCV Test and High Pure System for extraction, detection and quantitation of HCV RNA in plasma and serum.
Gelderblom HC; Menting S; Beld MG
Antivir Ther; 2006; 11(1):95-103. PubMed ID: 16518965
[TBL] [Abstract][Full Text] [Related]
20. HEp2 ANA EIA: a new fully automated assay for the screening of antinuclear antibodies.
Lehmann HP; Fühling I; Ott C; Hüdepohl B; Haass M
Isr Med Assoc J; 2000 Aug; 2(8):646-8. PubMed ID: 10979370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
